Clinical Trials Logo

ER+ HER2- Advanced Breast Cancer clinical trials

View clinical trials related to ER+ HER2- Advanced Breast Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04541433 Active, not recruiting - Clinical trials for ER+ HER2- Advanced Breast Cancer

A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer

Start date: September 29, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label study designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AZD9833 in Japanese women with endocrineresistant ER+ HER2- breast cancer that is not amenable to treatment with curative intent. This study consists of 2 cohorts, Cohort1 and Cohort2. In cohort 1 (for tolerability evaluation), a minimum of 3, or up to 6, evaluable Japanese patients with ER+ HER2- breast cancer will be enrolled. In cohort 2 (for exploratory research), at least 6 to maximum 12 evaluable Japanese patients with ER+ HER2- breast cancer will be enrolled.

NCT ID: NCT03616587 Active, not recruiting - Clinical trials for ER+ HER2- Advanced Breast Cancer

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

SERENA-1
Start date: October 11, 2018
Phase: Phase 1
Study type: Interventional

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER Positive, HER2 Negative Advanced Breast Cancer (SERENA-1)